The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more. Prices (Fares, Fees and Rates), Drugs (Pharmaceuticals), Health Insurance and Managed Care, Suits and Litigation (Civil), Presidential Election of 2024, Drugstores, Insulin, Regulation and Deregulation of Industry, CIGNA Corporation, CVS Caremark Corporation, Express Scripts Inc, Federal Trade Commission, Khan, Lina The case takes aim at the major pharmacy benefit managers, agency officials said, claiming that they favored more expensive insulin products and forced patients to pay more. NYT > Business
F.T.C. Accuses Drug Middlemen of Inflating Insulin Prices
